PRO Data Can Help When Deciding Between Neoadjuvant FOLFOX or Fluorouracil-Based Chemoradiation for Locally Advanced Rectal Cancer
Patient reported outcomes from the PROSPECT study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Patient reported outcomes from the PROSPECT study
New indication concerns the third-line treatment of metastatic colorectal cancer in combination with bevacizumab
Evidence for efficacy is based on the results from the TALAPRO-2 study
Findings from the DESTINY-Gastric02 study
Findings from the SYMPLIFY study
Findings from the TRESR study
Findings from a retrospective cohort study
Findings from the COLIBRI study
Evidence for efficacy is based on the results from the NP30179 study
Findings from the FRESCO-2 study
Findings from a retrospective analysis of older patients with newly diagnosed cancer who underwent G8 screening
Findings from the IND227 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.